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CD19 Regulates Src Family Protein Tyrosine
Kinase Activation in B Lymphocytes
through Processive Amplification
Altering CD19 density on the cell surface in gene-tar-
geted or transgenic mice significantly alters B cell func-
tion. B cells from CD19-deficient (CD192/2) mice are
hyporesponsive to transmembrane signals and gener-
ate modest immune responses (Engel et al., 1995; Rick-
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By contrast, overexpression of CD19 in transgenic mice²Department of Laboratory Medicine and
³Department of Microbiology and Immunology results in B cells that are hyperresponsive to transmem-
brane signals, elevated humoral immune responses, andUniversity of California, San Francisco
San Francisco, California 94143 disrupted tolerance with autoantibody production (Zhou
et al., 1994; Engel et al., 1995; Sato et al., 1995, 1996,
1997b, 1997c; Inaoki et al., 1997). Thus, CD19 functions
as a general rheostat that defines signaling thresholdsSummary
critical for expansion of the peripheral B cell pool (Ted-
der, 1998).CD19 regulates constitutive and antigen receptor±
induced signaling thresholds in B lymphocytes through CD19 is part of a multimolecular complex that inter-
sects with multiple intracellular signaling pathways (Fuji-its unique cytoplasmic domain. Herein, we demon-
strate a novel molecular mechanism where interac- moto et al., 1998). The 240 amino acid cytoplasmic re-
gion of CD19 contains nine conserved tyrosine residuestions between CD19 and Lyn amplify basal and antigen
receptor±induced Src family kinase activation. Lyn ex- (Tedder and Isaacs, 1989). Tyrosine phosphorylation of
CD19 following BCR and/or CD19 ligation provides Srcpression was required for CD19 tyrosine phosphoryla-
tion in primary B cells. Experiments with purified pro- homology 2 (SH2) recognition motifs that recruit regula-
tory molecules to the cell surface. CD19 dually phos-teins demonstrated that CD19-Y513 was Lyn's initial
phosphorylation and binding site. This led to pro- phorylated at CD19±Y482 and CD19±Y513 binds the tan-
dem SH2 domains of phosphatidylinositol 3-kinase (PIcessive phosphorylation of CD19-Y482, which recruited
a second Lyn molecule, allowing for transphosphory- 3-kinase) p85 subunit (Tuveson et al., 1993). Cell lines
transfected with CD19 cDNAs encoding mutations oflation and amplification of Lyn activation. In vivo, CD19
deficiency impaired, and CD19 overexpression en- CD19±Y482 and CD19±Y513 do not phosphorylate the other
seven tyrosines within the CD19 cytoplasmic tail (Tuve-hanced, Lyn kinase activity. Thus, CD19 functions as
a specialized adapter protein for the amplification of son et al., 1993; Buhl and Cambier, 1999). Although
these findings are interpreted to show that Y482 and Y513Src family kinases that is crucial for intrinsic and anti-
gen receptor±induced signal transduction. are the only two phosphorylated tyrosines in CD19, this
is paradoxical since recruitment of Vav to the cell surface
through phosphorylated CD19±Y391 is important for VavIntroduction
phosphorylation and activation (Weng et al., 1994; Li et
al., 1997; Sato et al., 1997a; O'Rourke et al., 1998). CD19Intrinsic and B cell antigen receptor (BCR) signaling re-
also recruits and regulates Src family PTKs since CD19quires protein tyrosine kinase (PTK) activation. Lyn, the
ligation can induce Lyn activation independent of BCRpredominant Src family member in B cells, has a crucial
expression (Uckun et al., 1993). In fact, Src family PTKinitiating role in BCR signaling and is essential for nega-
activation is impaired in B cells from CD192/2 mice (Fuji-tive feedback regulation (DeFranco et al., 1998). Intrinsic
moto et al., 1999b). Reciprocally, CD19 expression byregulation of Src family PTKs is mediated by phosphory-
a plasmacytoma cell line enhances Lyn tyrosine phos-lation of two different tyrosine residues, which recipro-
phorylation when compared with parental CD19-nega-cally regulate kinase activity (Sicheri and Kuriyan, 1997).
tive cells (Buhl et al., 1997). Recombinant CD19 alsoPTK function is also regulated by ªcross-talkº between
amplifies Lyn kinase activity in vitro (Fujimoto et al.,PTKs, protein tyrosine phosphatases, and interactions
1999b). However, it remains unknown how CD19 regu-with intracellular regulatory and adapter proteins. Re-
lates Src family PTK activation since CD19 itself doescently, we have suggested that a B lymphocyte cell
not have intrinsic kinase, phosphatase or known enzy-surface molecule, CD19, also regulates Src family PTK
matic function. Herein, we demonstrate a novel molecu-activation during BCR signaling (Fujimoto et al., 1999b).
lar mechanism through which CD19 amplifies Src familyCD19 plays a proximal role in BCR signaling by recruiting
PTK activity. This provides a mechanistic explanationSrc family PTKs, especially Lyn (Chalupny et al., 1993;
of how CD19 regulates basal signaling thresholds andRoifman and Ke, 1993; Uckun et al., 1993; van Noesel
accelerates BCR signaling.et al., 1993).
CD19 is a B lymphocyte±specific member of the im-
munoglobulin superfamily expressed by early pre-B Results
cells until plasma cell differentiation (Tedder et al., 1994).
Lyn Phosphorylates CD19 In Vivo
The role of Lyn in CD19 phosphorylation was examined§ To whom correspondence should be addressed (e-mail: thomas.
tedder@duke.edu). using B cells from Lyn2/2 mice. Splenic B cells from
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Figure 1. Two-Way Regulation between CD19 and Lyn In Vivo
(A) CD19 density on splenocytes from Lyn2/2 (bold line) and wild-type (solid line) mice. Immunofluorescence staining used FITC-conjugated
anti-CD19 mAb or an isotype-matched control mAb (dashed line) with flow cytometry analysis.
(B) CD19 tyrosine phosphorylation in splenic B cells from Lyn2/2 mice. B cells (1.5 3 107/sample) were incubated with anti-IgM antibody for
the times shown, lysed, and incubated with beads bearing either anti-CD19 or isotype-matched control (CTL) mAb. Immunoprecipitated
proteins were resolved by SDS-PAGE, transferred to nitrocellulose, and immunoblotted with anti-phosphotyrosine (anti-PTyr) antibody. The
blot was reprobed with rabbit anti-CD19 cytoplasmic domain antibody.
(C) Lyn protein levels in B cells from CD192/2, wild-type, and CD19TG mice. Cell lysates (106 cells) were subjected to SDS-PAGE and transferred
to nitrocellulose for immunoblotting with anti-Lyn antibody. The blot was reprobed with an anti-b-actin antibody.
(D) Lyn tyrosine phosphorylation in B cells from CD192/2, wild-type, and CD19TG mice. Splenic B cells were lysed after IgM ligation for 0 s
or 90 s. Proteins immunoprecipitated from cell lysates (107 cells/lane) with anti-Lyn antibody and protein G-Sepharose beads were analyzed
by anti-PTyr immunoblotting. The blot was reprobed with anti-Lyn antibody.
(E) Lyn kinase activity following IgM ligation in B cells from CD192/2, wild-type, and CD19TG mice. B cell activation and immunoprecipitations
were as in (D). The beads were then incubated with cdc2(6±20)NH2 peptide and [g-32P]ATP for 2 min at 258C. Mean (6 SEM) kinase activity
from three sets of mice is shown as percentage of wild-type B cell results at 0 min, in which the background and unstimulated wild-type B
cell levels were defined as 0% and 100%, respectively. An asterisk indicates a significantly different sample mean from wild-type mice; p ,
0.05.
(F) Vav phosphorylation following IgM ligation in B cells from CD19TG and wild-type mice. Immunoprecipitations and immunoblotting were
as described above using Vav-specific antibodies. All results represent those obtained in greater than three experiments.
Lyn2/2 and wild-type mice expressed CD19 at identical B cells from CD192/2 mice and mice that express a
human CD19 transgene (CD19TG). Since human andlevels (Figure 1A). Purified B cells were stimulated by
BCR ligation with optimal concentrations of F(ab9)2 mouse CD19 are functionally equivalent in vivo (Sato et
al., 1997c), CD19TG B cells express CD19 at 3-foldanti-IgM antibody and lysed with detergent. Proteins
immunoprecipitated from lysates with anti-CD19 anti- higher levels than those from wild-type littermates (En-
gel et al., 1995; Sato et al., 1997c). Both CD192/2 andbody-conjugated beads were resolved by SDS-PAGE,
transferred to nitrocellulose membranes, and probed CD19TG B cells expressed Lyn at wild-type levels (Fig-
ure 1C). Basal tyrosine phosphorylation of Lyn immuno-with a phosphotyrosine-specific monoclonal antibody
(mAb). CD19 phosphorylation was not detected in rest- precipitated from purified B cells appeared similar be-
tween CD192/2 and wild-type B cells (Figure 1D).ing or activated Lyn2/2 B cells even after 15 min of BCR
ligation (Figure 1B). By contrast, CD19 was constitutively However, Lyn phosphorylation was lower in CD192/2 B
cells after BCR ligation. By contrast, constitutive andtyrosine phosphorylated in wild-type B cells, with signifi-
cantly increased phosphorylation following BCR ligation BCR-induced tyrosine phosphorylation of Lyn was
higher in CD19TG B cells than in wild-type B cells (Figure(Figure 1B). Thus, Lyn is likely to mediate CD19 tyrosine
phosphorylation. 1D). Moreover, basal Lyn kinase activity was decreased
slightly in B cells from CD192/2 mice, but was signifi-
cantly higher in CD19TG B cells (Figure 1E). After BCRCD19 Expression Regulates Lyn and Vav Activation
Impaired Src family PTK activation is a hallmark of ligation, induced Lyn activity was significantly lower in
CD192/2 B cells and significantly increased in CD19-CD192/2 B cells (Buhl et al., 1997; Fujimoto et al., 1999b).
Therefore, a correlation between CD19 expression and overexpressing B cells (Figure 1E). Augmented Lyn ac-
tivity in CD19TG B cells was functionally significant sinceLyn kinase activity was assessed using purified splenic
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Figure 2. Lyn Phosphorylation Sites in CD19
(A and B) Schematic representation of (A) synthetic peptides containing the nine Tyr (Y) residues found in mouse CD19 and (B) human
CD19±GST fusion proteins used in this study. Amino acid numbering and exon boundaries are based on human CD19 sequences (Zhou et
al., 1991, 1992).
(C) Lyn phosphorylation of CD19 peptides. Purified bovine Lyn and biotinylated CD19 peptides were incubated with [g-32P]ATP. The reaction
mixtures were spotted onto biotin-capture membrane, and the incorporated radioactivity was quantified by scintillation counting. Incubation
of peptides without Lyn and incubation of phosphorylated CD19±Y513 peptide with Lyn are shown as controls. The vertical dashed line indicates
control levels of radioactivity.
(D) Lyn phosphorylation of CD19±GST fusion proteins. Purified Lyn and CD19 GST fusion proteins were incubated with [g-32P]ATP, followed
by SDS-PAGE. Relative levels of radioactivity were quantified using a PhosphorImager. Incubation of control GST protein with Lyn is shown
as a control.
(C and D) Values represent the mean (6 SEM) of results from three independent experiments. Mean values significantly different from controls
are indicated; *p , 0.05, **p , 0.01.
Vav was constitutively phosphorylated in CD19TG B and Y513 are preferred sites for Lyn-mediated phosphory-
cells, but not in wild-type B cells (Figure 1F). After BCR lation.
ligation, Vav was rapidly phosphorylated and Vav phos- Lyn phosphorylation of CD19 was further assessed
phorylation was significantly elevated in CD19TG B using glutathione S-transferase (GST) fusion proteins
cells. Therefore, the absence of CD19 expression im- that included the majority of the cytoplasmic domain
pairs Lyn and Vav activation, while CD19 overexpression (exons 7±14) or exons 7±13, 7±10, 8±12, 12±14, and 14
augmented both basal and induced Lyn kinase activity (Figure 2B). During in vitro kinase assays with purified
and Vav phosphorylation. Lyn, the near full-length exon 7±14 protein was the most
heavily phosphorylated, while GST was not phosphory-
lated (Figure 2D). Consistent with CD19±Y513 being aCD19-Y391 and CD19-Y513 Are Efficient Lyn Substrates
major phosphorylation site, phosphorylation of the exonCD19 tyrosine residues phosphorylated by Lyn were
12±14 protein was 81% 6 5% as much as the exon 7±14identified by in vitro kinase assays using nine peptides
protein. The exon 8±12 and 7±10 proteins contained Y391,corresponding to regions of the CD19 cytoplasmic do-
which may explain their 58% 6 1% and 54% 6 2%main (Figure 2A). The biotinylated CD19 peptides were
levels of phosphorylation, respectively, relative to theincubated with purified Lyn and [g-32P]ATP before blot-
exon 7±14 protein. Paradoxically, exon 14 protein wasting onto a biotin-capture membrane. All of the CD19
not strongly phosphorylated despite the presence ofpeptides incorporated radioactivity, except the CD19±
CD19±Y513. The exon 7±13 fusion protein was also poorlyY330 peptide (Figure 2C). However, Lyn phosphorylated
phosphorylated relative to all other fusion proteinsthe CD19±Y391 and CD19±Y513 peptides at .4-fold higher
levels than the other peptides. This suggests that Y391 (16% 6 1% of exon 7±14 protein phosphorylation).
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not precipitated by nonphosphorylated CD19 peptides
(data now shown). Thus, Lyn binding to CD19 was direct
and was likely to be mediated through Lyn's SH2
domain.
All six CD19 phosphopeptides that bound Lyn had
Glu at position 11 C-terminal to the Tyr residue (Figure
2A). The importance of Glu at this position was assessed
using mutant CD19 peptides corresponding to the tyro-
sine-phosphorylated (Y*) CD19±Y513 peptide with a
Y*ENM motif. Substitution of Glu with Gly (Y*GNM) re-
sulted in a complete loss of Lyn binding (Figure 3B).
Substitution of Met at position 13 in the CD19±Y513 pep-
tide with Gly (Y*ENG) significantly reduced Lyn binding,
suggesting that the 13 residue synergistically influences
binding (Figure 3B). Thus, the CD19±Y513 motif appears
to be a preferential Lyn phosphorylation and SH2 do-
main binding site.
Syk and Btk were not precipitated by phosphorylated
CD19 peptides (Figure 3A). Vav was precipitated primar-
ily with phosphopeptide Y391, but was also precipitated
with Y421, Y403, and Y513 phosphopeptides (Figure 3A). The
Grb2 adapter protein was bound primarily by Y330 (as
recently described by Brooks et al., 2000) and Y403 phos-
phopeptides and weakly by Y513 phosphopeptide. CD19
phosphopeptides did not precipitate detectable Shc
adapter protein. PI 3-kinase was precipitated by the
CD19±Y482 and Y513 phosphopeptides as shown pre-
Figure 3. Interactions between Signaling Molecules and CD19 viously (Tuveson et al., 1993). These proteins were not
Phosphopeptides
precipitated at detectable levels by nonphosphorylated
(A) Precipitation of Lyn, Fyn, Syk, Btk, Vav, Grb2, Shc, and PI CD19 peptides (data not shown). Thus, the pattern of
3-kinase using CD19 phosphotyrosine (Y*) peptides. Lysates of A20
Lyn binding to CD19 appeared specific to the Src familycells (2 3 107 cells) were incubated with each biotinylated CD19
PTKs.peptide bound to Streptavidin beads. Beads precoated with biotin
were used as negative controls (CTL), and whole-cell lysates from
7.5 3 105 cells were used as positive controls (Lysate). Precipitated Mapping CD19 Regions that Amplify Lyn
proteins were resolved by SDS-PAGE, transferred to nitrocellulose, Kinase Activity
and the membranes were probed with antibodies to each protein.
The region of CD19 involved in amplification of Lyn ki-(B) Precipitation of Lyn from lysates of A20 cells using CD19±Y513
nase activity (Fujimoto et al., 1999b) was assessed usingpeptides with or without the indicated mutations or phosphorylation.
Results represent those obtained in three or more experiments, CD19 peptides and CD19±GST fusion proteins (Figure
except the PI 3-kinase results represent two experiments. 2). Equimolar concentrations of each peptide, CD19±
GST fusion protein, or GST alone were added to in vitro
kinase assays with purified Lyn, [g-32P]ATP, and cdc2(6±
Nonetheless, these results are consistent with Y513 and 20)NH2 peptide as an exogenous substrate. CD19±GST
Y319 being significant Lyn phosphorylation substrates. and Lyn were used at a 50:1 molar ratio to reduce the
potential for nonspecific oligomerization of Lyn on a
limited supply of CD19 substrate. Lyn's kinase activityLyn Binding Sites in CD19
Since Src family PTK binding parallels CD19 tyrosine was significantly enhanced by the presence of CD19
exon 7±14 GST fusion protein over time as comparedphosphorylation after BCR ligation (Fujimoto et al.,
1999b), Lyn binding sites within CD19 were identified with GST alone (473% 6 16% of control at 15 min, p ,
0.001; Figure 4A). Incorporated radioactivity reflectedusing nine CD19 phosphopeptides (Figure 2A). These
biotinylated peptides precipitated multiple signaling kinase activity rather than substrate specificity since
.80% of 32P uptake was by cdc2 peptide rather thanmolecules from detergent lysates of mouse A20 cells,
a mature B cell line. Lyn was precipitated most efficiently GST fusion protein or Lyn autophosphorylation (data not
shown and Fujimoto et al., 1999b). The CD19 exon 12±14by the Y513 phosphopeptide, but also strongly by Y391,
Y421, or Y482 and weakly by Y403 and Y443 phosphopeptides protein was similar to exon 7±14 protein in its ability to
amplify Lyn activation, while exon 7±13, 7±10, 8±12, or(Figure 3A). The same CD19 phosphopeptides precipi-
tated Fyn (Figure 3A). Although these binding sites for 14 fusion proteins were similar to GST alone (Figure 4A).
Identical experiments were simultaneously carried outFyn differ from a previous study (Chalupny et al., 1995),
this may be due to differences in the CD19 peptides. with purified Lyn and CD19 fusion proteins alone. Lyn
autophosphorylation and CD19 fusion protein phos-To verify that Lyn binds CD19 directly, purified Lyn
was incubated with each phosphopeptide in separate phorylation were visualized either by 32P uptake or West-
ern blotting with an anti-phosphotyrosine mAb. The re-assays. Each of the CD19 phosphopeptides that precipi-
tated Lyn from cell lysates precipitated purified Lyn to sults from those studies paralleled the results shown in
Figure 4A, except 32P uptake was 5-fold lower in thea similar extent (data not shown). Lyn and Fyn were
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not affect Lyn activity during in vitro kinase assays (Fig-
ure 4B).
The ability of CD19 peptides to activate Lyn was as-
sessed since some phosphopeptides can activate Src
family PTKs during SH2 domain interactions (Clark et
al., 1994; Ruzzene et al., 1997). Addition of each CD19
phosphopeptide (Figure 4C) or unphosphorylated pep-
tide (data not shown) to in vitro kinase assays did not
affect Lyn activity when compared with the CD19±GST
fusion protein. Therefore, the ability of CD19 to amplify
Lyn kinase activity appears specific to CD19 exons
12±14 rather than just individual phosphopeptide se-
quences.
CD19-Y482 and CD19-Y513 Are Required to Amplify
Lyn Kinase Activity
Whether tyrosines within CD19 exons 13±14 were essen-
tial for amplification of Lyn kinase activity was assessed
using fusion proteins in which Y482 and/or Y513 were sub-
stituted with phenylalanine(s) (Figure 2B). The intact
CD19 exon 12±14 protein optimally augmened Lyn auto-
phosphorylation and CD19 phosphorylation during in
vitro kinase assays (Figure 5A). Phosphorylation of the
CD19±Y482F mutant protein was markedly reduced com-
pared with the intact protein, demonstrating that Y482
is a Lyn phosphorylation site. By contrast, CD19±GST
fusion proteins lacking an intact Y513 residue were not
phosphorylated by Lyn (Figure 5A). Thus, CD19±Y513
phosphorylation is required before subsequent CD19±
Y482 phosphorylation. Furthermore, Lyn autophosphory-
lation was not induced when mutated fusion proteins
or GST were added to the in vitro kinase assays (Figure
5A), indicating that intact Y482 and Y513 residues were
both required to amplify Lyn kinase activation.
That CD19±Y513 was required for CD19±Y482 phosphor-
ylation was shown directly by tryptic digestion of CD19±
GST fusion proteins that were purified following Lyn in
vitro kinase assays. Trypsin cleaves GST from the fusion
Figure 4. CD19 Amplifies Lyn Kinase Activity In Vitro proteins and generated seven major CD19 peptides
In vitro kinase assays using purified Lyn and the indicated (A) CD19± from the exon 7±14 proteins and four major peptides
GST fusion proteins, (B) CD22±GST fusion protein, or (C) CD19 phos- from the exon 12±14 proteins (Figure 2B). When the
phopeptides. Lyn and the indicated proteins were incubated with CD19±GST fusion proteins were purified and extensively
ATP for 2 min, followed by the addition of excess cdc2(6±20)NH2 digested with trypsin, the CD19 exon 12±14 protein gen-peptide and [g-32P]ATP for the indicated times (10 min in [C]). Lyn
erated two phosphorylated fragments, one containingkinase activity was evaluated by measuring incorporated radioactiv-
Y513 and a smaller fragment containing Y482 (Figure 5B).ity using a scintillation counter. Results represent those obtained
in at least three experiments. In (C), values represent the mean (6 The CD19±Y482F mutant protein yielded only the Y513
SEM) of results from three experiments. Mean values significantly phosphorylated peptide fragment after digestion (Fig-
different from controls are indicated; **p , 0.01. ure 5B). Peptides generated from CD19±Y513F and
CD19±Y482/513F proteins were not labeled. In control ex-
periments not shown, extensive incubation of the CD19±absence of cdc2(6±20)NH2 peptide (data not shown). It
was important, however, that Lyn autophosphorylation Y513F mutant protein with Lyn and [g-32P]ATP resulted in
low-level labeling of the Y482 phosphorylated fragment,correlated with its enzymatic activity in the in vitro kinase
assays (Figure 5A), as previously shown (Fujimoto et al., but not the larger Y513F peptide. No peptides were la-
beled after extensive incubation of the CD19±Y482/513F1999b). This suggests that CD19 exons 12±13 and exon
14 are necessary to amplify Lyn's enzymatic activity. protein with Lyn and [g-32P]ATP, demonstrating that Lyn
does not phosphorylate Y490. Therefore, efficient phos-To confirm that amplification of Lyn kinase activity
was unique to CD19, a GST fusion protein encoding phorylation of Y482 by Lyn required Y513 phosphorylation.
Only the intact CD19 exon 12±14 protein augmentedthe 140 amino acid cytoplasmic domain of CD22 was
assessed for its ability to amplify Lyn kinase activity. Lyn enzymatic activity during in vitro kinase assays us-
ing cdc2 peptide as a substrate (493% 6 79% of controlCD22 has six well-conserved tyrosine residues distrib-
uted throughout its cytoplasmic domain that provide at 15 min; Figure 5D). CD19 proteins with mutated Y513F
residues (100% 6 4% of GST alone), mutated Y482Fsubstrates for Lyn phosphorylation and binding (Poe et
al., 2000). However, the CD22±GST fusion protein did (153% 6 6%), or both Y482/513F mutations (105% 6 6%)
Immunity
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Figure 5. CD19±Y482 and Y513 Are Required for Amplification of Lyn Kinase Activity
(A) Lyn autophosphorylation and tyrosine phosphorylation of mutated CD19 exon 12±14 proteins during in vitro kinase assays. Purified Lyn
and CD19 proteins were incubated with ATP before SDS-PAGE, transfer to nitrocellulose, and anti-phosphotyrosine immunoblotting. Molecular
weight standards (31023) are shown on the left. The membrane was reprobed with an anti-GST antibody.
(B) Tryptic mapping of phosphorylated CD19 exon 12±14 proteins. Wild-type and mutated exon 12±14 proteins were incubated with Lyn and
[g-32P]ATP, subjected to SDS-PAGE, transferred to nitrocellulose, extensively digested with TPCK-trypsin, and subjected to native PAGE on
a 40% acrylamide gel with autoradiography.
(C) Tryptic mapping of phosphorylated CD19 exon 12±14, exon 7±14, exon 7±14 Y513F, and exon 8±12 proteins as described in (B) and resolved
on a 35% acrylamide gel.
(D) In vitro kinase assays using purified Lyn and mutated CD19 exon 12±14 proteins. Each kinase reaction was incubated with ATP for 2 min,
followed by the addition of excess cdc2(6±20)NH2 peptide and [g-32P]ATP for the indicated times. Lyn kinase activity was evaluated by
assessing incorporated radioactivity.
(E) In vitro kinase assays were carried out using biotinylated Lyn, 32P-labeled Lyn, and the indicated CD19 exon 12±14 proteins free of GST
with or without ATP. Equivalent concentrations of biotinylated and 32P-labeled Lyn were added to each kinase reaction. After 10 min, biotinylated
Lyn was isolated from the kinase reaction using streptavidin beads. After the beads were extensively washed, bound proteins were subjected
to SDS-PAGE and autoradiography.
(F) Vav phosphorylation during in vitro kinase assays. Each reaction contained purified Vav protein and ATP, plus the indicated CD19 proteins
or GST, with or without Lyn present. Vav phosphorylation was assessed by immunoblotting. These data represent results from at least three
experiments.
failed to amplify Lyn activation. When preparations of Lyn activity (Figure 4C and data not shown). Thus, the
linkage and spatial distribution of Y482 and Y513 are indis-ªpreactivatedº Lyn with high levels of endogenous tyro-
sine phosphorylation were used in these assays, the pensable for amplification of Lyn kinase activity.
presence of CD19 exon 12±14 fusion protein did not
enhance Lyn activity (data not shown). Thus, the CD19- Processive Amplification of Lyn Kinase Activity
and Vav Phosphorylationinduced increase in Lyn enzymatic activity resulted from
enhanced conversion of Lyn to an activated state rather Whether two Lyn molecules assemble on phosphory-
lated Y482 and Y513 of the same CD19 molecule duringthan enhancing the enzymatic activity of activated Lyn.
The spatial distribution of CD19±Y482 and CD19±Y513 Lyn amplification was tested directly. GST was enzymat-
ically cleaved from CD19 exon 12±14 fusion proteinswas critical for amplifying Lyn kinase activity as as-
sessed using a mutated CD19 exon 12±14 fusion protein. and removed to avoid potential dimerization of CD19
via GST. Lyn labeled with biotin and Lyn labeled withShortening the distance between Y482 and Y513 from 30
to 20 amino acids by deleting residues 494±503 resulted 32P were added to in vitro kinase assays containing CD19
exon 12±14 peptides and cold ATP. Following the kinasein a 40% reduction in the ability of the exon 12±14 protein
to amplify Lyn kinase activation (data not shown). The assay, biotinylated Lyn was precipitated from the reac-
tion mixture, extensively washed, and subjected to SDS-simultaneous addition of both CD19±Y482 and CD19±Y513
peptides or both CD19±GST Y482F and CD19±GST Y513F PAGE with autoradiography. Biotin-labeled Lyn copre-
cipitated 32P-labeled Lyn from the reaction when intactfusion proteins to in vitro kinase assays did not affect
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CD19 exon 12±14 peptide was added with ATP (Figure
5E). By contrast, 32P-labeled Lyn was not coprecipitated
when ATP was left out of the reaction mixture. Therefore,
dual phosphorylation of CD19 peptides by Lyn results
in the recruitment of two Lyn molecules on single CD19
peptides. As further controls, CD19 peptides with mu-
tated Y482, Y513, or Y482/513 residues did not coprecipitate
32P-labeled Lyn with biotinylated Lyn. Thus, CD19 phos-
phorylation induced the processive assembly of two Lyn
molecules on one CD19 molecule.
Whether CD19 amplification of Lyn kinase activity in-
fluenced phosphorylation of other CD19 tyrosines was
assessed by trypsin digestion of CD19 fusion proteins
after in vitro kinase assays. Trypsin digestion of CD19
exon 7±14 proteins (Figure 2C) generated a phosphory-
lated fragment containing Y391±Y443 and two smaller
phosphorylated fragments also observed in exon 12±14
proteins (Figure 5C). Phosphorylation of the Y391±Y443
fragment was diminished significantly when generated
from the exon 8±12 protein but was even lower when
generated from exon 7±14 protein lacking CD19±Y513.
Augmented Y391±Y443 fragment phosphorylation was
functionally significant since Vav phosphorylation dur-
ing Lyn in vitro kinase assays was enhanced significantly Figure 6. CD19 Tyrosine Phosphorylation and Associations with
by the presence of CD19 exon 7±14 protein compared Lyn and PI 3-Kinase
with exon 12±14 protein (Figure 5F). Thus, phosphory- (A) Splenic B cells (1.5 3 107/lane) from wild-type mice were incu-
lated CD19 functions as an adapter protein to bring bated with anti-IgM antibodies for the times shown. CD19 was im-
munoprecipitated from cell lysates and analyzed by anti-phospho-Vav into physical proximity with activated Lyn, which
tyrosine immunoblotting. The blot was reprobed with PI 3-kinase-,amplifies Vav phosphorylation and activation.
Lyn-, and CD19-specific antibodies. Whole-cell lysate (3 3 106 cells/
sample) is shown as a positive control.
Formation of CD19/Lyn and CD19/PI 3-Kinase (B and C) The means (6 SEM) of results obtained in four experiments
Complexes in Primary B Cells are shown as graphs.
(B) CD19 phosphorylation levels were quantified by densitometry,The physiological significance of two-way interactions
with CD19 phosphorylation in unstimulated B cells defined as 100%.between CD19 and Lyn was further assessed using pri-
(C) Lyn and PI 3-kinase associated with CD19 as a percentage ofmary B cells. Since PI 3-kinase binds dually phosphory-
the amount of each immunoreactive protein in the whole-cell lysate.
lated CD19±Y482 and CD19±Y513 (Tuveson et al., 1993; Lyn and PI 3-kinase concentrations were estimated based on their
Weng et al., 1994; Chalupny et al., 1995; Beckwith et relative intensities.
al., 1996; Li et al., 1997), this interaction was further
assessed by immunoprecipitating CD19 from primary B
cells before and after BCR ligation (Figure 6A). The rela- (Chan et al., 1997), it is unlikely that Syk or other kinases
tive amounts of Lyn and PI-3 kinase associated with phosphorylate CD19 initially. Furthermore, in a cell line
CD19 was assessed and compared with increased lev- expressing dominant-negative Syk, CD19 is phosphory-
els of CD19 phosphorylation (Figures 6B and 6C). Almost lated normally following BCR ligation (Beitz et al., 1999).
2% of cellular Lyn was constitutively associated with After phosphorylation, CD19 appears to have a specific
CD19 in primary B cells and BCR engagement increased preference for Src family PTK binding (Figure 3A). Sub-
Lyn's binding to CD19 by z2-fold (Figure 6C). By con- sequently, endogenous CD19 expression levels regulate
trast, BCR ligation in wild-type B cells was required to Lyn kinase activity in primary B cells (Figures 1D and
induce a significant association between PI 3-kinase 1E). Specifically, CD19 appears to serve as a specialized
and CD19 (Figures 6A and 6C). However, the amount of adapter protein for mediating functional interactions be-
PI 3-kinase precipitated with CD19 increased more than tween two Src family PTK molecules recruited to phos-
10-fold after BCR ligation. This suggests that PI 3-kinase phorylated CD19 through their respective SH2 domains
binds CD19 following Lyn's dual phosphorylation of (Figure 7). This process, termed ªprocessive amplifica-
CD19±Y482 and Y513. Thus, processive phosphorylation tion,º allows CD19 to regulate basal signal transduction
of CD19 by Lyn may influences subsequent PI 3-kinase thresholds and magnify B cell activation following BCR
and Vav binding. and/or CD19 ligation. This represents a novel mecha-
nism for kinase activation and CD19 function.
CD19 amplified Src family PTK activity directlyDiscussion
through a small region of its cytoplasmic domain en-
coded by exons 12±14 (Figure 4A). Alterations in eitherThis study demonstrates a series of molecular interac-
tions between cell surface CD19 and intracellular Lyn CD19±Y482 or Y513 eliminated the ability of recombinant
CD19 proteins to amplify Lyn kinase activity and Lynthat generates a Src family kinase amplification loop.
First, Lyn expression was required for CD19 phosphory- autophosphorylation (Figure 5). Thus, two Lyn mole-
cules juxtaposed by binding phosphorylated CD19±Y482lation in primary B cells (Figure 1B). Since other kinases
are activated to near-normal levels in Lyn2/2 B cells and Y513 are likely to reciprocally transphosphorylate and
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collective results suggest that Lyn has two preferential
phosphorylation sites, CD19±Y391 and Y513 (Figures 2C
and 5C), with phosphorylated CD19±Y513 being a pre-
ferred Lyn binding site (Figure 3A). The C-terminal loca-
tion of CD19±Y513 is consistent with a model of ªpro-
cessive phosphorylationº where a C-terminal SH2
domain binding site in target substrates enhances Src
family PTK phosphorylation of N-terminal tyrosines
(Mayer et al., 1995; Songyang and Cantley, 1995). More-
over, tryptic mapping of CD19 phosphorylation sites
within exons 12±14 demonstrated that CD19±Y513 was
required for tyrosine phosphorylation of CD19±Y482 (Fig-
ure 5B). Since CD19±Y482 peptides were not optimal sub-
strates for Lyn phosphorylation (Figure 2C), the localiza-
tion of Y482 proximal to Y513 may be critical for optimal
Y482 phosphorylation. Thereby, phosphorylated CD19±
Y513 acts as a nucleation site to retain Lyn, which then
phosphorylates N-terminal CD19 tyrosines through pro-
cessive phosphorylation. Since phosphorylation of Src
family PTKs downregulates the ligand binding capacity
of their SH2 domains (Sotirellis et al., 1995; Couture et
al., 1996), Lyn may reduce its affinity for CD19 following
activation and allow the subsequent recruitment of un-
activated Lyn to CD19±Y482 or Y513 residues. Continued
recruitment of unactivated Lyn would perpetuate a Src
family PTK amplification loop. In support of this, Lyn
Figure 7. Model for Processive Amplification of Lyn Activity by phosphorylation and binding to CD19 appeared to pre-
CD19 cede PI 3-kinase recruitment (Figure 6).
Following BCR and/or CD19 ligation, (A) Lyn phosphorylates ex- Processive phosphorylation of CD19 explains hereto-
posed CD19±Y513. (B) Subsequently, Lyn binds phosphorylated fore contradictory in vivo results that CD19 proteins with
CD19±Y513 via its SH2 domain and phosphorylates CD19±Y482 mutated Y482 and Y513 residues are not phosphorylated on
through ªprocessive phosphorylation.º (C) Phosphorylated CD19±
other tyrosines (Tuveson et al., 1993; Buhl and Cambier,Y482 recruits another Lyn molecule, which leads to Lyn transphos-
1999). Rather, phosphorylation of CD19±Y482 and Y513phorylation and/or autophosphorylation. CD19 phosphorylation in-
promotes further processive phosphorylation of CD19duces conformational changes that allow phosphorylation of
CD19±Y391. (D) Phosphorylated CD19±Y391 recruits Vav, which is sub- (Figure 5C). Vav was principally bound by CD19±Y391
sequently phosphorylated by Lyn. Once activated, Lyn may lose its phosphopeptides, consistent with the findings of others
SH2 domain binding affinity and release CD19, thereby allowing the (O'Rourke et al., 1998), although Vav also bound to other
recruitment of unactivated Lyn into an CD19-mediated Src family
CD19 phosphopeptides (Figure 3A). Indeed, the intactPTK amplification loop. Lyn release from CD19 may allow the tan-
CD19 cytoplasmic domain augmented Vav phosphory-dem SH2 domains of PI 3-kinase to interact with CD19±Y482 and
lation during in vitro assays beyond the effect of ampli-CD19±Y513.
fying Lyn kinase activity (Figure 5D and 5F; Fujimoto et
al., 1999b). Consistent with this, CD19 overexpression
activate each other (Figure 5E and Figure 7). Other accelerated and increased the magnitude of Vav phos-
proximal regions of CD19 may also influence Lyn amplifi- phorylation in primary B cells following BCR ligation
cation through protein±protein interactions, and Lyn ac- (Figure 1F). Since CD19±Y391 was phosphorylated effi-
tivation may be enhanced further by CD19 oligomeriza- ciently by Lyn (Figure 2C) and Vav is not phosphorylated
tion on the cell surface in vivo. However, enhanced Lyn in Lyn-deficient B cells (Nishizumi et al., 1995), Lyn phos-
enzymatic activity by CD19 was not a sole consequence phorylation of CD19 is likely to be important for optimal
of SH2 domain engagement or Lyn C-terminal tail dis- Vav phosphorylation. CD19 expression is required for
placement since CD19 phosphopeptides or CD19 exon optimal Vav phosphorylation (Sato et al., 1997a). In fact,
7±13 and exon 14 proteins, alone or in combination, CD19, Lyn and Vav form a constitutively assembled
failed to augment Lyn activity (Figure 4C; data not shown). complex in B cells that increases following BCR ligation
Thereby, CD19 is distinct from the BCR ITAMs and other (Fujimoto et al., 1999b). Thus, CD19 functions as an
single-site phosphopeptides that amplify Src kinase ac- effective adapter protein to recruit Vav and promote
tivity (Clark et al., 1994). Thus, kinase recruitment to Lyn's phosphorylation of Vav.
specific proximal CD19 tyrosines represents a novel Processive phosphorylation of CD19 may also explain
mechanism by which CD19 regulates B cell signaling why the CD19±Y391 peptide was efficiently phosphory-
responses. lated by Lyn, while the CD19 exon 7±13 fusion protein
The in vitro kinase assays carried out with purified that included Y391 was poorly phosphorylated relative to
Lyn and CD19 peptides and fusion proteins recapitulate other shorter fusion proteins (Figure 2D). Tryptic map-
the CD19 phosphorylation patterns predicted and ob- ping of CD19 phosphorylation sites reinforced this ob-
served in vivo (Tuveson et al., 1993; Uckun et al., 1993; servation since CD19 exon 8±12 protein was phosphory-
van Noesel et al., 1993; Weng et al., 1994; Li et al., 1997; lated at higher levels than exon 7±14 Y513F protein (Figure
5C). An explanation for these paradoxical observationsO'Rourke et al., 1998; Buhl and Cambier, 1999). These
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Purified bovine Lyn and cdc2(6±20)NH2 peptide were from Upstatemay be that the CD19 cytoplasmic domain is highly
Biotechnology. Biotinylated Lyn and 32P-labeled Lyn were preparedfolded due to its unique patches of charged residues
using EZ-link sulfo-NHS-biotin (Pierce) and autophosphorylation,(Zhou et al., 1991). Thereby, phosphorylation of CD19±
respectively. After autophosphorylation, free [g-32P]ATP was re-
Y513 may be required to ªunfoldº the CD19 cytoplasmic moved using Centricon 10 concentrators (Amicon). CD19 peptides
domain before other tyrosines are phosphorylated (Fig- were synthesized by the University of North Carolina Protein Se-
quence and Peptide Facility.ure 7). Thus, in the absence of Y513, the CD19 cytoplasmic
Plasmids encoding wild-type and mutant CD19±GST fusion pro-domain may assume an ªinaccessibleº conformation.
teins were generated by PCR amplification of human CD19 cDNAsDeleting portions of CD19, as occurs with the exon 7±10
(Tedder and Isaacs, 1989) with ligation into pGEX-3X (Pharmaciaand exon 8±12 proteins, may prevent CD19 folding and
Biotech). Plasmids encoding CD19 exon 8±12 and exon 12±14 fusion
allow unregulated phosphorylation of exposed tyro- proteins were provided by Dr. M. Grove (Duke University). The CD22±
sines. Since Lyn bound six of the nine CD19 phosphoty- GST fusion protein was as described (Poe et al., 2000). All plasmid
inserts were verified by DNA sequence analysis. The fusion proteinsrosine motifs (Figure 3A), cytoplasmic domain folding
were produced in E. coli DH5a and purified with glutathione-agarosemay render these binding sites inaccessible and thereby
beads (Pharmacia Biotech). GST was removed from CD19 proteinspromote Lyn's initial phosphorylation of, and binding to,
by digestion with Factor Xa (Pharmacia Biotech) and removal of GSTCD19±Y513. Conformational regulation of CD19 phos-
from the solution with glutathione-agarose beads. Fusion protein
phorylation may also control its interactions with other concentrations were determined by quantitative protein staining
signaling molecules. after SDS-PAGE using SYPRO Orange protein gel stain (Molecular
Probes).The processive amplification mechanism proposed in
this study explains in large part the opposing pheno-
B Cell Activation and Immunoprecipitationstypes of CD192/2 mice and mice that overexpress CD19.
Splenic B cells were stimulated with F(ab9)2 fragments of goat anti-Since CD19 alone was sufficient to amplify Src family
mouse IgM antibody (40 mg/ml) at 378C and lysed in buffer containingPTK activation in vitro without manipulation, the consti-
1% Nonidet P-40 as described (Fujimoto et al., 1999b). For immuno-
tutive assembly of CD19/Lyn/Vav complexes may estab- precipitations, the cell lysates were incubated with protein-G beads
lish basal signaling thresholds. In the absence of CD19 (Pharmacia Biotech) plus the appropriate antisera or mAb at opti-
expression, Lyn activity would persist, albeit without mized concentrations for 4 hr at 48C. CD19 was immunoprecipitated
using MB19±1 mAb bound to Affigel 10 beads (Bio-Rad). For precipi-amplification. This would explain why CD192/2 B cells
tations with CD19 peptides, A20 cells (2 3 107) were lysed in 500are hyporesponsive to transmembrane signals. Consis-
ml of 1% Nonidet P-40 lysis buffer and incubated for 30 min at 258Ctent with this, mutation of CD19±Y482 and Y513 diminishes
with 50 ml of streptavidin-agarose beads (Pierce) precoated with
BCR-induced signals in a B cell line (Buhl et al., 1997). each biotinylated CD19 peptide.
That CD19 can amplify kinase activity autonomously
also explains why B cells from mice that overexpress Western Blotting
CD19 are phenotypically similar to chronically stimu- Cell lysates or precipitated proteins were subjected to SDS-PAGE
with electrophoretic transfer to nitrocellulose membranes. Blotslated B cells in the absence of antigen challenge. Fur-
were incubated with either HRP-conjugated anti-phosphotyrosinethermore, this explains their hyperresponsiveness to
mAb (4G10, Upstate Biotechnology; or PY99, Santa Cruz Biotech-transmembrane signals. Thereby, the CD19/Src family
nology) or, alternatively, with antibody against the proteins of inter-
PTK amplification loop is likely to regulate basal signal est with subsequent incubation with HRP-conjugated anti-rabbit or
transduction thresholds and magnify B cell activation anti-mouse IgG antibody (Jackson Immunoresearch Laboratories),
following antigen receptor and/or CD19 engagement. followed by enhanced chemiluminescence (Pierce). The blots were
then stripped and reprobed with appropriate control antibodies. ForMoreover, the ability of CD19 to amplify Src family PTK
quantitation of band intensities, autoradiographs were scanned andactivation reveals a novel mechanism for regulating cel-
analyzed using NIH Image software (version 1.60).lular signaling thresholds and responses.
In Vitro Lyn Kinase Assays
Experimental Procedures The kinase activity of Lyn immunoprecipitated from purified B cell
lysates was quantified as described (Fujimoto et al., 1999a). After
Cells washing in lysis buffer and in reaction buffer (50 mM Tris-HCl [pH
CD192/2, CD19TG, and Lyn2/2 mice were as described (Zhou et al., 7.4], 10 mM MgCl2, 0.1 mM Na o-vanadate, 1 mM DTT), beads
1994; Engel et al., 1995; Chan et al., 1997) and were housed in a bearing immunoprecipitated Lyn were incubated at 258C for 2 min
specific pathogen-free barrier facility. Wild-type littermates from in 50 ml of reaction buffer containing cdc(6±20)NH2 peptides (10 mg),
heterozygous matings or age-matched C57BL/6 wild-type mice 2 mM MnCl2, and 10 mCi of [g-32P]ATP. The reactions were termi-
were used appropriately as controls. All procedures were approved nated by adding 40% TCA and spotted onto p81 phosphocellulose
by the Animal Care and Use Committee of Duke University. Splenic paper (Life Technologies) that was washed and subjected to scintil-
B cells were purified by removing Thy1.21 cells with antibody-coated lation counting. Lyn activity in the presence of CD19±GST fusion
magnetic beads (Dynal, Inc.). A20 cells were cultured in RPMI 1640 protein was quantified using similar assays. CD19±GST fusion pro-
medium (Life Technologies) supplemented with 10% calf serum and tein or GST (3 mM) and purified bovine Lyn (17.5 U) were incubated
2-mercaptoethanol. in 140 ml of reaction buffer containing 10 mM ATP at 258C. After 2
min, cdc2 peptide (70 mg) and [g-32P]ATP (70 mCi) in 70 ml were
added to the reaction mixtures. At specific incubation times, 30 mlReagents
Antibodies used in these studies were reactive with: Lyn, Fyn, Btk, of the reaction was removed, added to 10 ml of 40% TCA, and
processed as above. Lyn activity in the presence of CD19 phospho-Syk, Vav, Grb2, and GST from Santa Cruz Biotechnology; PI
3-kinase, Shc, and Vav from Upstate Biotechnology; b-actin from peptides was assessed using similar assays: CD19 peptides (3 mM)
and Lyn (2.5 U) were preincubated with ATP for 2 min, followed bySigma; F(ab9)2 fragments of goat anti-mouse IgM antibody from
Cappel; mouse CD19 (MB19±1, Sato et al., 1996); and rabbit anti- the addition of cdc2 peptide and [g-32P]ATP. In some experiments,
the in vitro kinase assays were carried out using equimolar amountsCD19 cytoplasmic domain antiserum (provided by Dr. M. Grove,
Duke University). Immunofluorescence analysis was as described of biotinylated Lyn and 32P-labeled Lyn. In these experiments, biotin-
ylated Lyn was precipitated from the reaction mixture using 50 ml(Zhou et al., 1994) using a FACScan flow cytometer (Becton Dick-
inson). of streptavidin-agarose beads, with extensive washing of the beads
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before SDS-PAGE. In other experiments, Vav immunoprecipitated Aruffo, A., and Ledbetter, J.A. (1993). Tyrosine phosphorylation of
CD19 in pre-B and mature B cells. EMBO J. 12, 2691±2696.from unstimulated A20 cells was added to each kinase reaction
(1.5 3 107 cell equivalents/reaction) for 10 min. Chalupny, N.J., Aruffo, A., Esselstyn, J.M., Chan, P.Y., Bajorath, J.,
Blake, J., Gilliland, L.K., Ledbetter, J.A., and Tepper, M.A. (1995).
Specific binding of Fyn and phosphatidylinositol 3-kinase to the BLyn Phosphorylation of CD19
cell surface glycoprotein CD19 through their src homology 2 do-Lyn phosphorylation of biotinylated CD19 peptides was assessed
mains. Eur. J. Immunol. 25, 2978±2984.by incubating CD19 peptide (250 mM), purified Lyn (2.5 U), and 10
mCi of [g-32P]ATP in 20 ml of reaction buffer for 10 min at 258C. Chan, V.W.F., Meng, F., Soriano, P., DeFranco, A.L., and Lowell,
C.A. (1997). Characterization of the B lymphocyte populations inReactions were terminated by adding guanidine HCl and spotted
Lyn-deficient mice and the role of Lyn in signal initiation and down-onto SAM2 Biotin Capture Membrane (Promega). The membranes
regulation. Immunity 7, 69±81.were washed with 2 M NaCl, 1 M NaCl 1 0.375% (v/v) phosphoric
acid, and 2 M NaCl containing 1% Tween 20. Radioactivity was Clark, M.R., Johnson, S.A., and Cambier, J.C. (1994). Analysis of
quantified by scintillation counting. Ig-alpha-tyrosine kinase interaction reveals two levels of binding
Lyn phosphorylation of CD19±GST fusion proteins was assessed specificity and tyrosine phosphorylated Ig-alpha stimulation of Fyn.
by incubating fusion protein (3 mM), Lyn (2.5 U), and 10 mCi of EMBO J. 13, 1911±1919.
[g-32P]ATP in 20 ml of reaction buffer for 10 min at 258C. The reaction Couture, C., Songyang, Z., Jascur, T., Williams, S., Tailor, P., Cantley,
was terminated by adding 23 sample buffer, followed by SDS-PAGE L.C., and Mustelin, T. (1996). Regulation of the Lck SH2 domain by
analysis. The incorporated radioactivity was quantified using a tyrosine phosphorylation. J. Biol. Chem. 271, 24880±24884.
PhosphorImager (Molecular Dynamics). DeFranco, A.L., Chan, V.W.F., and Lowell, C.A. (1998). Positive and
Tryptic mapping of CD19 phosphorylation sites used described negative roles of the tyrosine kinase Lyn in B cell function. Semin.
methods (Aebersold et al., 1987). After in vitro Lyn kinase assays, Immunol. 10, 299±308.
the CD19±GST fusion proteins were resolved by SDS-PAGE and
Engel, P., Zhou, L.-J., Ord, D.C., Sato, S., Koller, B., and Tedder,transferred to nitrocellulose. Membrane fragments containing the
T.F. (1995). Abnormal B lymphocyte development, activation andCD19 protein bands were excised, blocked by 1.5% polyvinylpyrroli-
differentiation in mice that lack or overexpress the CD19 signaldone 40 in 100 mM acetic acid, and incubated overnight with 20
transduction molecule. Immunity 3, 39±50.
mg of TPCK-trypsin (Sigma) at 378C in 200 ml of 0.05 M NH4HCO3.
Fujimoto, M., Poe, J.C., Inaoki, M., and Tedder, T.F. (1998). CD19After adding an additional 20 mg of trypsin with further incubation
regulates B lymphocyte responses to transmembrane signals.for 6 hr, the cleaved peptides were separated by native PAGE (West
Semin. Immunol. 10, 267±277.et al., 1984) and subjected to autoradiography.
Fujimoto, M., Bradney, A.P., Poe, J.C., Steeber, D.A., and Tedder,
T.F. (1999a). Modulation of B lymphocyte antigen receptor signalStatistics
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